Navigation Links
Favrille Announces $21.1 Million Registered Direct Offering
Date:11/2/2007

nufacturing and marketing FavId or Favrille's other product candidates; delays in the availability of data from Favrille's Phase 3 clinical trial; Favrille's ability to obtain marketing approval for FavId or Favrille's other product candidates and the timing of any such approvals, including whether a clinically meaningful response improvement can serve as the basis for accelerated approval of FavId and whether it will receive expedited review as a result of the Fast Track designation; Favrille's ability to demonstrate that its idiotype protein produced from insect cell lines may stimulate a more effective immune response compared to idiotype protein derived from mammalian cells; Favrille's ability to manufacture sufficient quantities of FavId for use in clinical trials and, if FavId receives marketing approval, for commercialization; risks associated with achieving projected operating metrics and financial performance or the anticipated number of patients using FavId; potential delays in patient enrollment; Favrille's ability to obtain additional financing to support its operations, including the conditions to the Company's ability to access the committed equity financing facility and therefore fund operations through the first half of 2008; and additional risks discussed in Favrille's filings with the Securities and Exchange Commission. In addition, conclusions regarding the safety and efficacy of Favrille's product candidates cannot be made until the results of future clinical trials of longer duration in more patients are known. All forward-looking statements are qualified in their entirety by this cautionary statement. Favrille is providing this information as of the date of this release and, except as required by law, does not undertake any obligation to update any forward-looking statements contained in this release as a result of new information, future events or otherwise.


'/>"/>
SOURCE Favrille, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Speaker announces business members of IT Task Force
2. Doyle announces technology tax credits for Berbee
3. Doyle announces new energy, global warming policies
4. Doyle announces $80M renewable energy strategy
5. GE announces first installation of Discovery VCT
6. UWM announces winners of RGI awards
7. Third Wave announces two senior management appointments
8. Mirus announces new method for making antibodies
9. Merge announces sofware updates, upcoming acquisition
10. Small Tree announces ethernet solution for Apple Xserv G5
11. TEKLYNX International announces new RFID software
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/6/2015)... SHENZHEN, China , May 6, 2015 ... http://www.beikebiotech.com ) – Beike Biotechnology, the world,s ... ,high-dose, umbilical cord derived mesenchymal stem cell packets containing ... pack. This new product could significantly reduce the ... and therapies, especially in the case of degenerative ...
(Date:5/6/2015)... May 6, 2015   University of Maryland (UM) ... today the signing of an exclusive option by Biomecite ... (UMB) to develop diagnostics to detect inflammatory bowel diseases ... (CD). Drs. Florian Fricke and James ... with the University of Maryland School of Medicine,s Institute ...
(Date:5/6/2015)... 6, 2015 Whitefox ( ... today that it has signed an agreement with  ... PEIX ) for the delivery of an industrial scale membrane ... consumption of water, energy and emissions in ... This project is fully aligned with ...
(Date:5/5/2015)... Frederick, MD (PRWEB) May 05, 2015 ... solutions provider released FreezerPro® version 7, the latest major ... management software., Upgrade is a ... Revamped UI succeeds in enhancing users experience, while also ... overall performance, reduces system requirements , Download ...
Breaking Biology Technology:Beike Biotechnology Produces High-dose Adult Stem Cell Packets for Degenerative Conditions 2Biomecite Diagnostics Signs Option Agreement with UM Baltimore to Develop Tools to Detect Inflammatory Bowel Diseases 2Biomecite Diagnostics Signs Option Agreement with UM Baltimore to Develop Tools to Detect Inflammatory Bowel Diseases 3Whitefox Signs Agreement With Pacific Ethanol Inc. 2RURO Releases version 7 of FreezerPro® software 2
... BOSTON, Jan. 4 PAREXEL International,Corporation (Nasdaq: PRXL ... on Wednesday, January 23, 2008 after the close of ... website at, http://www.parexel.com and on the PR Newswire ... conference call and live webcast at 10:00 a.m. ET,on ...
... SOUTH SAN FRANCISCO, Calif., Jan. 4 Cerimon,Pharmaceuticals, ... been named,General Counsel, a newly established position, and ... is a global life sciences,executive and corporate attorney ... early-stage companies in the US and,Europe. In the ...
... If Approved for Marketing in the United States, Trade Name Will be ... ... Daiichi Sankyo,Company, Limited (TSE: 4568) and Eli Lilly and Company (NYSE: ... a New Drug,Application (NDA) for prasugrel to the U.S. Food and Drug ...
Cached Biology Technology:PAREXEL Announces Date of Second Quarter Fiscal Year 2008 Earnings Release and Conference Call 2Cerimon Pharmaceuticals Names Matthew J. Meyer its General Counsel and Vice President of Business Development and Licensing 2Daiichi Sankyo, Lilly Submit New Drug Application for Investigational Antiplatelet Drug, Prasugrel, with U.S. Food and Drug Administration 2Daiichi Sankyo, Lilly Submit New Drug Application for Investigational Antiplatelet Drug, Prasugrel, with U.S. Food and Drug Administration 3Daiichi Sankyo, Lilly Submit New Drug Application for Investigational Antiplatelet Drug, Prasugrel, with U.S. Food and Drug Administration 4
(Date:3/24/2015)... March 24, 2015   Crossmatch ™, a ... announced that its U.are.U ® 4500 Fingerprint ... Goorin Bros . to achieve PCI compliance for ... access to the POS terminal, protecting the retailer ... data breaches. With one-third of ...
(Date:3/23/2015)... 23, 2015   HOYOS Labs , a leading ... announced that the Company will demonstrate multiple biometrics-based technologies ... consumers at Connect:ID on March 23 through 25, 2015, ... will highlight the IEEE Biometric Open Protocol Standard; free ... enterprise access control system. BOPS was invented by HOYOS ...
(Date:3/23/2015)... , Mar. 23, 2015 NXT-ID, Inc. (NASDAQ: NXTD ... on the growing mobile commerce market, announces its biometric payment ... campaign on CNBC television starting March 30 th . ... airing in New York markets. ... "We are excited about our new ad campaign following the ...
Breaking Biology News(10 mins):Crossmatch Fingerprint Readers Help Retailer Prevent Data Breaches at Point-of-Sale 2HOYOS Labs to Showcase Host of Biometrics Technologies at Connect:ID in Washington, D.C. 2HOYOS Labs to Showcase Host of Biometrics Technologies at Connect:ID in Washington, D.C. 3NXT-ID's Wocket Smart Wallet to Launch New CNBC Regional TV Ad Campaign 2NXT-ID's Wocket Smart Wallet to Launch New CNBC Regional TV Ad Campaign 3
... in the environmentand in environmental science laboratories. Because they ... and antifungal agents, silver nanoparticles increasingly are being used ... This, in turn, has raised concerns about what happens ... new research paper* adds an additional wrinkle: Nature may ...
... have almost lifted the curtain on the long-awaited era of the ... up a person can be deciphered for about that amount ... article in the current edition of Chemical & Engineering News (C&EN), ... of $100,000, by one conservative estimate, is necessary to analyze that ...
... expensive cancer drugs, dubbed "smart drugs" for their ability to ... are not effective in some patients. In two related studies, ... EGF receptor (EGFR), and found that a decoy receptor might ... intended target. "We know that smart drugs like ...
Cached Biology News:Silver cycle: New evidence for natural synthesis of silver nanoparticles 2Yale researchers explain why cancer 'smart drugs' may not be so smart 2
AADAC Immunogen: AADAC (NP_001077, 201 a.a. ~ 301 a.a) partial recombinant protein with GST tag. Storage: -20 C, Avoid Freeze/Thaw Cycles *Available for distribution in the US only...
Mouse monoclonal [CIa] to Ia Antigen (Biotin) ( Abpromise for all tested applications)....
Goat polyclonal to FBXO2 ( Abpromise for all tested applications). entrezGeneID: 26232 SwissProtID: Q9UK22...
Phospho-TAK1 (Thr184/187) (90C7) Rabbit mAb Shipping Temperature: Cold Storage Temperature: -20C...
Biology Products: